Kashiwagi Eiji, Abe Tatsuro, Kinoshita Fumio, Ushijima Miho, Masaoka Hiroyuki, Shiota Masaki, Netto George J, Eto Masatoshi, Miyamoto Hiroshi
Department of Urology, Kyushu University Graduate School of Medical Sciences Fukuoka 8128582, Japan.
Department of Pathology and James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine Baltimore, MD 21287, USA.
Am J Transl Res. 2020 Jun 15;12(6):3033-3045. eCollection 2020.
Adipocytokines such as leptin and adiponectin have functions in metabolism as well as the development and progression of various types of malignancies. However, little is known about their role in bladder cancer. In this study, we investigated whether leptin, adiponectin, and their receptors have an impact on bladder cancer outgrowth and the mechanisms involved. We performed immunohistochemistry for leptin, leptin receptor (Ob-R), adiponectin, and adiponectin receptors (AdipoR1, AdipoR2) in bladder cancer tissue microarrays. Wound healing assay and western blot were then performed in human bladder cancer lines. The positive rates (0 vs 1+/2+/3+) of Ob-R (P=0.004), adiponectin (P<0.001), AdipoR1 (P=0.016), and AdipoR2 (P<0.001) expression were significantly higher in bladder tumors than in benign urothelial tissues. Strong (3+) leptin expression tended to be present more often in tumors (10.2%; P=0.079) than in benign tissues (3.2%). Multivariate analysis revealed a lower risk of recurrence (hazard ratio [HR]=0.432; 95% confidence interval [CI]=0.198-0.942; P=0.034) in patients with an adiponectin-positive non-muscle-invasive tumor and a higher risk of progression (HR=5.148, 95% CI=1.190-22.273; P=0.028) in patients with a leptin-positive muscle-invasive tumor. Treatment of two bladder cancer cell lines with a synthetic adiponectin inhibited their migration and the expressions of phospho-NF-κB, NF-κB, snail, slug, Y-box-binding protein 1, and COX-2, whereas leptin showed reverse effects. Downregulation of adiponectin expression and upregulation of leptin expression were independent predictors for the recurrence of non-muscle-invasive bladder tumors and progression of muscle-invasive bladder tumors, respectively. In summary, synthetic adiponectin might exhibit antitumor activity against bladder cancer.
瘦素和脂联素等脂肪细胞因子在新陈代谢以及各类恶性肿瘤的发生和发展过程中发挥作用。然而,它们在膀胱癌中的作用却鲜为人知。在本研究中,我们调查了瘦素、脂联素及其受体是否对膀胱癌的生长及相关机制产生影响。我们对膀胱癌组织芯片进行了瘦素、瘦素受体(Ob-R)、脂联素及脂联素受体(AdipoR1、AdipoR2)的免疫组化检测。随后在人膀胱癌细胞系中进行了伤口愈合试验和蛋白质印迹分析。与良性尿路上皮组织相比,膀胱癌组织中Ob-R(P = 0.004)、脂联素(P < 0.001)、AdipoR1(P = 0.016)和AdipoR2(P < 0.001)表达的阳性率(0级与1 + /2 + /3 +级)显著更高。强(3 +)瘦素表达在肿瘤组织(10.2%;P = 0.079)中出现的频率往往高于良性组织(3.2%)。多因素分析显示,脂联素阳性的非肌层浸润性肿瘤患者复发风险较低(风险比[HR] = 0.432;95%置信区间[CI] = 0.198 - 0.942;P = 0.034),而瘦素阳性的肌层浸润性肿瘤患者进展风险较高(HR = 5.148,95% CI = 1.190 - 22.273;P = 0.028)。用合成脂联素处理两种膀胱癌细胞系可抑制其迁移以及磷酸化核因子κB、核因子κB、蜗牛蛋白、蛞蝓蛋白、Y盒结合蛋白1和环氧化酶-2的表达,而瘦素则表现出相反的作用。脂联素表达下调和瘦素表达上调分别是非肌层浸润性膀胱肿瘤复发和肌层浸润性膀胱肿瘤进展的独立预测因素。总之,合成脂联素可能对膀胱癌具有抗肿瘤活性。